Abstract:Background: Alpha-synuclein oligomers (o-α-syn) are pivotal in the pathogenesis of α-synucleinopathy. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) serves as an early indicator of the disease, offering insights into disease mechanisms and early intervention. Nevertheless, the diagnostic and predictive potential of o-α-syn in iRBD remains largely unexplored. This study aimed to evaluate the plasma levels of o-α-syn in patients and investigate their utility as biomarkers for diagnosis of and predicting phenoconversion in iRBD. Methods: A total of 143 participants, including 77 polysomnography-confirmed iRBD patients and 66 normal controls (NC), were recruited for this longitudinal observational study. Baseline clinical assessments and plasma collection were conducted for all iRBD patients, with 72 of them undergoing regularly prospective follow-up assessments for parkinsonism or dementia. Plasma levels of o-α-syn were quantified using enzyme-linked immunosorbent assay, and were compared between groups using a general linear model adjusted for age and sex. The diagnostic performance of plasma o-α-syn in iRBD was evaluated by area under the receiver operating characteristic curve (AUC) with 95% CI. Cox regression analysis and Kaplan-Meier survival curves were employed to assess the predictive value of plasma o-α-syn for phenoconversion in iRBD. Results: Plasma o-α-syn levels did not exhibit statistically significant differences among iRBD converter patients, iRBD nonconverter patients, and NC. The AUC for distinguishing NC from iRBD was 0.52 (95% CI: 0.42-0.62, p = 0.682). Spearman correlation analysis revealed a significant positive correlation between plasma o-α-syn levels and MOCA scores in the iRBD group (p < 0.001). Subgroup analyses indicated that iRBD patients with cognitive decline (p = 0.058) and depressive symptoms (p = 0.017) had notably lower o-α-syn levels compared to those without such symptoms. Over a median follow-up period of 5.83 years, 26 iRBD patients developed neurodegenerative synucleinopathies. Cox regression and Kaplan-Meier survival curve analyses indicated that plasma level of o-α-syn lacked a predictive value for disease conversion in iRBD patients. Conclusion: Despite a potential role in the pathophysiology of iRBD, o-α-syn are not appropriate biomarkers for diagnosing or predicting disease progression. While this study offers insights into the pathogenesis of iRBD and neurodegenerative synucleinopathies, further large-scale longitudinal studies are warranted to validate these findings.

Impaired Ocular Tracking and Cortical Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Abnormal Eye Movements in Patients with Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Different Patterns of Exosomal Α‐synuclein Between Parkinson's Disease and Probable Rapid Eye Movement Sleep Behavior Disorder

Structural and functional brain alterations in patients with idiopathic rapid eye movement sleep behavior disorder

Predictors of Conversion to -Synucleinopathy Diseases in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Gray Matter Structural Alterations in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: A Voxel-based Meta-Analysis

Retinal Nerve Fiber Layer Thinning: a Window into Rapid Eye Movement Sleep Behavior Disorders in Parkinson’s Disease

Brain olfactory-related atrophy in isolated rapid eye movement sleep behavior disorder

Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson’s disease and normal control

Alterations of Brain Structural Network in Parkinson’s Disease with and Without Rapid Eye Movement Sleep Behavior Disorder

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Biomarkers of conversion to -synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Clinical Biomarkers of Neurodegeneration in REM Sleep Behavior Disorder

Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder

Assessing Gray Matter Volume in Patients with Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Facilitatory/inhibitory intracortical imbalance in REM sleep behavior disorder: early electrophysiological marker of neurodegeneration?

Functional Neuroimaging in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder

Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder

Plasma level of alpha-synuclein oligomers as a biomarker for isolated rapid eye movement sleep behavior disorder diagnosis and progression: a prospective cohort study

Altered Nigrostriatal and Nigrocortical Functional Connectivity in Rapid Eye Movement Sleep Behavior Disorder